Related Experiment Video
Updated: Aug 9, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Stage I corpus cancer: is teletherapy necessary?
J W Orr1, J L Holimon, P F Orr
1Division of Gynecologic Oncology, Patty Berg Cancer Center, Columbia Regional Medical Center, Southwest Florida, USA.
American Journal of Obstetrics and Gynecology
|April 1, 1997
Summary
Extensive surgical staging with hysterectomy and lymphadenectomy is safe for endometrial cancer. Patients with surgical stage I disease not receiving teletherapy showed good survival and low recurrence rates.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
- Cancer Research
Background:
- Endometrial cancer treatment often involves hysterectomy and lymphadenectomy.
- The role of adjunctive teletherapy in early-stage disease is debated.
- Evaluating surgical morbidity and oncologic outcomes is crucial.
Purpose of the Study:
- To assess perioperative morbidity following hysterectomy and lymphadenectomy for endometrial cancer.
- To analyze recurrence and survival rates in stage I endometrial cancer patients without teletherapy.
Main Methods:
- A 10-year retrospective study of 444 patients undergoing extensive surgical staging for corpus cancer.
- Prospective recording of perioperative events and updated outcome data.
- Exclusion of high-risk histologic types, resulting in 396 evaluable patients.
Main Results:
- Surgical morbidity (e.g., infection, thromboembolism, injury) was comparable to less extensive procedures.
- Late complications like lymphocyst and hernia were infrequent.
- Five-year survival for stage I disease was 97%, with variations by stage (IA 100%, IB 97%, IC 93%).
Conclusions:
- Extensive surgical staging, including lymphadenectomy, is a safe primary treatment for endometrial cancer.
- Adjunctive teletherapy may not be necessary for all stage I patients, as pelvic recurrence and survival risks are not compromised.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.